GLOW Blend 70mg
EXPRESS Apple Pay afterpay
GLOW Stack at a glance
Inside the GLOW 70mg blend
GLOW combines three distinct materials. GHK-Cu accounts for approximately 71.4% of the nominal total by mass, while BPC-157 and TB-500 each represent approximately 14.3%.
GHK-Cu
Copper-peptide complex investigated in extracellular-matrix, dermal-cell and collagen-associated research.
BPC-157
Synthetic pentadecapeptide investigated in preclinical tendon, ligament, muscle and gastrointestinal research models.
TB-500
Peptide component associated with thymosin beta-4 fragment research and experimental cellular processes.
The 70mg specification describes nominal composition, not a measured batch total. The quantity of GHK-Cu refers to the copper-peptide complex, not 50mg of elemental copper.
Three distinct research pathways
GLOW Stack is not one new peptide molecule. Its scientific background comes from the separate research literature for GHK-Cu, BPC-157 and TB-500-associated materials.
GHK-Cu & matrix biology
Studies involving GHK-Cu investigate collagen- and elastin-associated cell responses, extracellular-matrix regulation and dermal-fibroblast activity.
BPC-157 & tissue models
Preclinical BPC-157 experiments have investigated tendon-cell survival, migration and outgrowth, alongside other musculoskeletal and gastrointestinal models.
TB-500 & cell migration
Published full-length thymosin beta-4 studies examine actin biology, cell migration and wound-related models. Those findings do not directly establish the effects of a TB-500-labelled fragment.
The individual component literature does not establish that the GLOW blend produces additive, synergistic or clinically meaningful effects.
What has the research investigated?
The available scientific literature investigates the ingredients individually, using different molecular materials, study designs and experimental systems.
GHK-Cu ยท Dermal fibroblast research
Experimental studies have examined the relationship between GHK-Cu and collagen-, elastin- and extracellular-matrix-associated signals in cultured dermal cells. Separate investigations have examined topical copper-peptide formulations.
Chang et al. ยท Journal of Applied Physiology (2011)
Researchers examined BPC-157 in tendon explants and cultured tendon cells, measuring cellular migration, survival and tendon outgrowth. These were experimental laboratory outcomes rather than established results for the GLOW combination.
Malinda et al. ยท Journal of Investigative Dermatology (1999)
Research involving full-length thymosin beta-4 examined wound-related experimental processes including cell migration, re-epithelialisation and angiogenesis. The study did not test the complete GLOW formulation.
Research limitations
A controlled human clinical trial establishing the safety or effectiveness of the complete GHK-Cu, BPC-157 and TB-500 mixture is not identified in the cited literature. Findings from individual compounds cannot be combined to create a clinical claim for the blend.
Experimental outcomes do not establish cosmetic, recovery, anti-ageing or therapeutic benefits from Halo Bio’s finished GLOW research vial.
GLOW Stack vs KLOW Stack
GLOW and KLOW are related catalogue formulations, but they contain different numbers of components and have different nominal total strengths.
| Characteristic | GLOW | KLOW |
|---|---|---|
| GHK-Cu | 50mg | 50mg |
| BPC-157 | 10mg | 10mg |
| TB-500 | 10mg | 10mg |
| KPV | Not included | 10mg |
| Total nominal strength | 70mg | 80mg |
| Number of components | Three | Four |
These are formulation differences, not evidence that either research blend is more effective than the other.
Melbourne stock. Nationwide dispatch.
Halo Bio holds stock in Melbourne and offers same-day dispatch for eligible in-stock orders placed before 2pm on business days, subject to payment confirmation. Tracking information is supplied during fulfilment, with delivery timing dependent on destination and carrier.
GLOW Stack research FAQs
GLOW Stack is a three-component laboratory research blend containing GHK-Cu, BPC-157 and TB-500 in a fixed-ratio formulation.
The nominal composition is 50mg GHK-Cu, 10mg BPC-157 and 10mg TB-500, giving a combined labelled total of 70mg.
GHK-Cu is a copper complex of the tripeptide glycyl-histidyl-lysine. It is investigated in extracellular-matrix and dermal-cell research.
BPC-157 is a synthetic 15-amino-acid peptide studied predominantly in preclinical tissue and gastrointestinal research models.
TB-500 refers to a peptide material associated with thymosin beta-4. The precise sequence and identity of the research material need to be confirmed using product-specific analytical documentation.
No. This 70mg GLOW formulation contains GHK-Cu, BPC-157 and TB-500. KPV is included in the separate four-component KLOW formulation.
GLOW contains three components and has a 70mg nominal total. KLOW contains the same three nominal quantities plus 10mg KPV, giving an 80mg labelled total.
The cited publications do not establish controlled human clinical evidence for the complete three-component GLOW formulation.
No. It is a combination of three distinct compounds in one vial, rather than one molecule with a single amino-acid sequence.
It represents the combined nominal mass of the three listed ingredients. It is not a batch-specific analytical measurement of identity, purity or content.
No established clinical evidence demonstrates skin, recovery or anti-ageing benefits from this complete research formulation. Individual ingredient studies cannot establish those claims for the combination.
No. Halo Bio supplies GLOW for laboratory research only, not for consumption, injection, self-administration or clinical treatment.
Eligible in-stock orders placed before 2pm on business days are dispatched from Melbourne the same day after payment confirmation.
Independent scientific publications
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival and cell migration. Journal of Applied Physiology, 2011.
Read publication โ - Malinda KM et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
Read publication โ - Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025.
- GHK-Cu research investigating collagen, elastin and extracellular-matrix signalling in cultured dermal fibroblasts.
- Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012.
These sources describe individual components or related molecular research, not controlled clinical trials of the finished GLOW blend.
Laboratory research use only.
Not intended for human or animal consumption, injection, self-administration, diagnostic use or clinical treatment. Published experimental findings do not establish the identity, purity, sterility, safety or performance of this separately supplied three-component research blend. Refer to batch-specific analytical documentation and verified laboratory handling instructions where available.